liraglutide glp 1 agonist A rising tide with Liraglutide is a GLP-1 Receptor

Multiple reviewers describe starting at very low doses (0.04 ml) and taking months to reach therapeutic levels, all while being charged $199-299/mo

Indications: FDA approved: Type II diabetes - monotherapy or combination therapy Can be combined as adjunct therapy with other hypoglycemics including metformin, thiazolidinediones, or insulin regimens (Dungan & DeSantis 2015) Because it does not work when your blood sugar is low, it is unlikely to produce dangerous levels of hypoglycemia has been observed in clinical trials (in contrast to GLP-1 incretin mimetics, such as exenatide, which produce moderate weight loss)

A new study is investigating whether higher doses of injectable GLP-1 agonist Trulicity (dulaglutide) are more effective

Liraglutide for psychiatric disorders: clinical evidence and challenges